| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 2 data readout example | Phase 2 | — | Subscribe to access the data. | Biologics | Oncology | ||
Phase 2 data readout example | Phase 2 | — | Subscribe to access the data. | Biologics | Oncology | ||
Phase 2 data readout example | Phase 2 | — | Subscribe to access the data. | Biologics | Oncology |
Recent Updates
Recently added Catalysts
Xilio Therapeutics, Inc.$9.1
-0.1 (-1.09%)
C 48Pipeline Score Undervalued Pharma · Clinical
Market Cap
49.36 M
EPS
-3.51
P/E Ratio
-
Value Trade
78.79 K
SEC Financials
Q1 2026Dilution Risk
Revenue
12.65 M
R&D Expenses
19.83 M
Operating CF
-22.34 M
Total Assets
163.49 M
Total Liabilities
90.94 M
Equity
72.55 M
D/E Ratio
12,345
-6.25 %
Week
-4.4 %
1 Month
0.73 %
3 Month
-21.43 %
6 Month
-96.07 %
5 Year
-96.07 %
All Time
Cash Data
Cash Position
150.33 M
Monthly Burn
7.45 M
Runway
18.5 mo
Burn Trend
SEC Filing
May 12, 2026
Overview
Volume
18.96 K
52 Week Range
6.47 - 16.10
% held by Insiders
54.44 %
% held by Institutions
19.58 %
Enterprise Value
-94.34 M
Total Shares
67.56 M
Short %
0.57 %
Float Shares
30.47 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Xilio Therapeutics, Inc.
277Total events
21Upcoming
56Tier-1 (high impact)
2021 – 2027Coverage
Upcoming catalysts 21
Event history 256
Q3 2026
◆Trial InitiationXTX501Trial
Phase 1 trial initiation for XTX501
metastatic non-small cell lung cancersource ↗
Jun 2026
◆Equity OfferingCorporate
Series C warrants exercisable for cash at $0.75 per share, potential $50M additional gross proceeds
Apr 20, 2026
◆Poster PresentationXTX601Presentation
Poster presentation of preclinical data for masked CLDN18.2-targeting T cell engager XTX601 at AACR 2026
cancersource ↗
Apr 17, 2026
◆Poster PresentationCLDN18Presentation
Poster presentation at AACR for CLDN18.2 program
gastrointestinal cancers, lung cancersource ↗
Apr 16, 2026
Q2 2026
◆Development Candidate NominationPreclinical
Development candidate nomination for PSMA/STEAP1 program
prostate cancersource ↗
Q2 2026
Apr 2026
●Poster PresentationXTX601Presentation
Preclinical data for XTX601 presented at AACR
gastrointestinal cancerssource ↗
Drug Pipeline Intelligence
C48
Pipeline Score $195M
Pipeline ValueUndervalued
Valuation Signal3
Drugs Scored4.0x
rNPV / MCap Top 71%
Micro Cap (rank 265 of 911)
Percentile RankXilio Therapeutics, Inc. carries a moderate pipeline score (48/100), with $4.7B risk-adjusted pipeline value, led by vilastobart in Advanced Solid Tumor (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| XTX202 Small molecule | Advanced Solid Tumor | Phase 1 | NCT05052268 | 5% | $1.6B | COMPLETED | 95 | - | - | Mar 25, 2025 | - | MEDIUM Jun 28, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
vilastobart | MSS metastatic colorectal cancer (mCRC) | Phase 2 | 2025-11-13 | In a late-breaking Phase 2 trial, vilastobart demonstrated a 40% overall response rate (ORR) in heavily pretreated patients with microsatellite stable metastatic colorectal cancer (mCRC) without liver metastases, highlighting its potential as a combination therapy. Read More | Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2025 Financial Results Read More | |
vilastobart | MSS metastatic colorectal cancer (mCRC) | Phase 2 | 2025-11-13 | In a late-breaking Phase 2 trial, vilastobart demonstrated a 40% overall response rate (ORR) in heavily pretreated patients with microsatellite stable metastatic colorectal cancer (mCRC) without liver metastases, highlighting its potential as a combination therapy. Read More | Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2025 Financial Results Read More | |
vilastobart | MSS metastatic colorectal cancer (mCRC) | Phase 2 | 2025-11-13 | In a late-breaking Phase 2 trial, vilastobart demonstrated a 40% overall response rate (ORR) in heavily pretreated patients with microsatellite stable metastatic colorectal cancer (mCRC) without liver metastases, highlighting its potential as a combination therapy. Read More | Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2025 Financial Results Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in XLO
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
XLO Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
XLOXilio Therapeutics Appoints Ben Harshbarger as Chief Legal Officer
Xilio Therapeutics has appointed Ben Harshbarger as its new Chief Legal Officer. Harshbarger, who has over 20 years of experience in the biopharmaceutical industry, will support the company's strategic goals as it advances its pipeline of immuno-oncology therapies. His previous roles include leadership positions at Astria Therapeutics and Novelion Therapeutics.
Read more →XLOXILIO THERAPEUTICS, INC. Condensed Consolidated Statements of Operations and Comprehensive Loss (In thousands, except share and per share data) (1) (Unaudited) Three Months Ended
Xilio Therapeutics, Inc. reported its financial results for the first quarter of 2026, highlighting advancements in its oncology pipeline, including potential best-in-class therapies targeting PD-1 and CLDN18.2. The company is preparing for an IND submission for XTX501, expected in mid-2026, and plans to initiate a Phase 1 trial later in the year. Additionally, financial results showed collaboration and license revenues of $12.6 million, reflecting increased productivity in its partnerships, particularly with AbbVie. Despite a net loss of $9.5 million during the quarter, Xilio’s cash position improved to $150.3 million, extending its financial runway into early 2028.
Read more →XLOXilio Therapeutics Reports First Quarter 2026 Financial Results and Provides Pipeline and Business Updates
Xilio Therapeutics reported financial results for Q1 2026 and provided pipeline updates, indicating strong momentum in its development programs. The company is on track to submit an IND application for its bispecific PD-1/masked IL-2 therapy XTX501 by mid-2026 and aims to initiate the Phase 1 trial later that year. Notably, Xilio presented promising preclinical data for its XTX601 program at the AACR Annual Meeting. The company also reported a cash position of $150.3 million as of March 31, 2026, which, along with recent milestones, positions it well for continued development.
Read more →XLOXilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 7, 2026
Xilio Therapeutics announced the grant of stock options to a new employee as part of its 2022 Inducement Stock Incentive Plan. The options, totaling 1,982 shares, have an exercise price of $8.32 and will vest over a ten-year term. This move aligns with Nasdaq Listing Rule 5635(c)(4) and reflects the company's commitment to attracting talent.
Read more →XLOXilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Xilio Therapeutics has granted non-qualified stock options to a new employee as part of its 2022 Inducement Stock Incentive Plan. The options, totaling 1,982 shares, have an exercise price of $8.32 per share and will vest over a period of time. This move is in accordance with Nasdaq Listing Rule 5635(c)(4) and reflects the company's commitment to attracting talent.
Read more →XLOXilio Therapeutics Announces New Preclinical Data at AACR Annual Meeting for XTX601, a Masked T Cell Engager Targeting CLDN18.2
Xilio Therapeutics has announced promising preclinical data for its masked T cell engager XTX601, targeting the CLDN18.2 antigen, at the AACR Annual Meeting. The data shows that XTX601 exhibits potent anti-tumor activity and is well tolerated in non-human primates, suggesting a favorable therapeutic index. The innovative design aims to minimize systemic toxicity while effectively engaging T cells against solid tumors. Xilio plans to advance XTX601 to IND-enabling studies with an IND application anticipated in 2027.
Read more →XLOXilio Therapeutics Appoints Cheryl R. Blanchard, Ph.D. to its Board of Directors
Xilio Therapeutics has appointed Cheryl R. Blanchard, Ph.D., to its board of directors, enhancing its leadership team. Blanchard, with over three decades of experience in life sciences, is expected to contribute significantly to the development of Xilio's masked immuno-oncology therapies. Christina Rossi has stepped down from the board, marking a leadership transition.
Read more →XLOXilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Xilio Therapeutics, a clinical-stage biotech company, announced the granting of non-qualified stock options to purchase 3,257 shares of common stock to two new employees. These grants are part of the company's 2022 Inducement Stock Incentive Plan and were effective from April 1, 2026. Each stock option has an exercise price of $8.48 per share and comes with a specific vesting schedule tied to employment duration.
Read more →XLOXilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2025 Financial Results
Xilio Therapeutics has announced significant progress in its pipeline, including the upcoming IND submission for XTX501, a bispecific PD-1 / masked IL-2 therapy, planned for mid-2026. The company is also advancing a multi-specific masked T cell engager targeting PSMA and STEAP1, with preclinical data presentation scheduled for the AACR Annual Meeting in April 2026. Xilio's financial results show a strong cash position, extending its runway through the end of 2027.
Read more →XLOXilio Therapeutics to Present New Preclinical Data for its Masked T Cell Engager Program Targeting CLDN18.2 at the American Association for Cancer Research (AACR) Annual Meeting
Xilio Therapeutics announced a poster presentation at the AACR Annual Meeting, showcasing new preclinical data for its masked T cell engager program targeting CLDN18.2. The presentation is scheduled for April 20, 2026, and aims to highlight advancements in immuno-oncology therapies designed to improve cancer treatment outcomes. The company emphasizes its commitment to minimizing systemic side effects.
Read more →XLO▼ -5.3%on this newsshared move
Xilio Therapeutics Announces 1-for-14 Reverse Stock Split
Xilio Therapeutics announced a 1-for-14 reverse stock split effective March 13, 2026, to boost its stock price and comply with Nasdaq listing requirements. The split, approved by shareholders, will reduce the number of outstanding shares from approximately 73.5 million to about 5.2 million. Trading on a split-adjusted basis will commence on March 16, 2026.
Read more →XLOUnlocking the Potential of Immuno-Oncology Therapies
Xilio Therapeutics is advancing its pipeline of immuno-oncology therapies leveraging clinically-validated masking technology. The company focuses on developing tumor-selective therapies that aim to maximize anti-tumor activity while minimizing severe side effects. Xilio reports promising clinical data with durable responses across various tumor types and maintains collaborations with key industry partners like AbbVie and Gilead. However, the company faces potential risks related to clinical trial timelines and other operational factors that could affect its development goals.
Read more →XLOXilio Therapeutics to Present at the Leerink Partners Global Healthcare Conference
Xilio Therapeutics announced its participation in the upcoming Leerink Partners Global Healthcare Conference, scheduled for March 9, 2026. The company's management will engage in a fireside chat, which will be accessible via a live webcast. Xilio is dedicated to developing masked immuno-oncology therapies aimed at improving cancer treatment outcomes.
Read more →XLO▲ +11.4%on this news
Xilio Therapeutics Announces Pricing of Underwritten Offering
Xilio Therapeutics announced the pricing of an underwritten offering of pre-funded warrants to purchase 74,780,300 shares of common stock at $0.5349 each. The offering is expected to close on February 13, 2026, and aims to raise around $40 million for product development and general corporate purposes. The financing was led by Coastlands Capital and included participation from several institutional investors.
Read more →XLO▼ -6%on this news
Xilio Therapeutics Highlights Upcoming Milestones and Recent Corporate Updates
Xilio Therapeutics has announced significant corporate updates, including the successful exercise of Series B warrants that raised $35.8 million, extending its cash runway into 2027. The company achieved a milestone under its AbbVie agreement and nominated Sara Bonstein as the new chair of the board. Xilio's leadership emphasized the importance of advancing its pipeline of masked immuno-oncology therapies.
Read more →XLO▼ -9.3%on this news
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2025 Financial Results
Xilio Therapeutics announced significant updates regarding its pipeline and financial results for Q3 2025. The company reported a 40% objective response rate for vilastobart in patients with MSS mCRC and presented promising data for efarindodekin alfa. Additionally, new preclinical data supports the potential of its masked T cell engager programs. Xilio anticipates a cash runway into Q1 2027.
Read more →XLOXilio Therapeutics Announces Late-Breaking Phase 2 Data for Vilastobart in Patients with MSS mCRC and High Plasma Tumor Mutational Burden at Society for Immunotherapy of Cancer (SITC) 40 th Annual Meeting 40% ORR in heav
Xilio Therapeutics announced promising Phase 2 data for vilastobart, demonstrating a 40% objective response rate in heavily pre-treated patients with microsatellite stable metastatic colorectal cancer (mCRC) and high plasma tumor mutational burden. The data, presented at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting, highlights a significant correlation between plasma TMB status and treatment response. This presents a potential avenue for improving treatment outcomes in a previously high unmet need population. Xilio is actively seeking collaboration to pursue further development of vilastobart with PD-(L)1 therapies.
Read more →XLOXilio Therapeutics Announces Late-Breaking Phase 2 Data for Vilastobart in Patients with MSS mCRC and High Plasma Tumor Mutational Burden at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting
Xilio Therapeutics announced promising Phase 2 data for vilastobart, showing a 40% objective response rate in heavily pre-treated patients with MSS mCRC and high plasma TMB. The data, presented at the SITC 40th Annual Meeting, suggests plasma TMB as a potential predictive biomarker for treatment response. The company plans to further develop vilastobart in combination with PD-(L)1 therapies.
Read more →XLOXilio Therapeutics Highlights Portfolio of Differentiated Masked Immunotherapies at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting
Xilio Therapeutics presented new data at the SITC 40th Annual Meeting, showcasing the promising potential of its masked T cell engager programs and clinical-stage therapies. Phase 1 results for efarindodekin alfa demonstrated anti-tumor activity in advanced solid tumors, while Phase 2 data for vilastobart indicated ctDNA could serve as a predictive biomarker for treatment response. The company aims to advance its innovative therapies to improve cancer treatment outcomes.
Read more →XLOXilio Therapeutics to Present Phase 2 Data for Vilastobart Highlighting Response Rate in Patients with MSS mCRC and High Plasma Tumor Mutational Burden as a Late-Breaking Presentation at SITC 40th Annual Meeting
Xilio Therapeutics is set to present Phase 2 data for its drug vilastobart at the SITC 40th Annual Meeting, focusing on patients with microsatellite stable (MSS) metastatic colorectal cancer (mCRC) who exhibit high plasma tumor mutational burden. The late-breaking presentation will highlight the drug's promising response rate when combined with atezolizumab. This showcase at a prominent cancer immunotherapy conference may enhance the visibility of Xilio's therapeutic strategy. However, the company faces various risks related to ongoing research and potential regulatory hurdles.
Read more →XLOXilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting
Xilio Therapeutics announced multiple poster presentations at the SITC 40th Annual Meeting, scheduled for November 6-9, 2025. The presentations will cover clinical data for vilastobart and efarindodekin alfa, as well as preclinical data on masked T cell engager programs. This event highlights Xilio's commitment to advancing immuno-oncology therapies.
Read more →XLO▲ +7.8%on this news
Xilio Therapeutics Announces Initiation of Phase 2 Trial for Efarindodekin Alfa (XTX301), a Tumor-Activated IL-12, and Achievement of $17.5 Million Development Milestone Under Exclusive License Agreement with Gilead
Xilio Therapeutics has announced the initiation of a Phase 2 trial for efarindodekin alfa (XTX301), a tumor-activated IL-12, following promising Phase 1 results. The company also achieved a $17.5 million milestone under its license agreement with Gilead, extending its financial runway into 2027. The trial aims to evaluate the drug's efficacy in patients with advanced solid tumors.
Read more →XLOXilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2025 Financial Results Announced updated Phase 2 data at ASCO for vilastobart, a tumor-activated, Fc-enhanced, anti-CTLA-4, demonstrating deep
Xilio Therapeutics has reported significant advancements in its pipeline, particularly highlighting updated Phase 2 data for vilastobart, an investigational anti-CTLA-4 therapy demonstrating favorable efficacy and safety. The company is poised to nominate its first masked T cell engager candidates in late 2025 and has provided encouraging updates on XTX301, its tumor-activated IL-12 therapy, in collaboration with Gilead. Financially, Xilio is secure with $121.6 million in cash, expected to last until the end of Q3 2026. Overall, the company is executing rapidly on its strategic goals in immuno-oncology research.
Read more →XLOXilio Therapeutics Appoints Akintunde Bello, Ph.D., to its Board of Directors
Xilio Therapeutics announced the appointment of Akintunde Bello, Ph.D., to its board of directors. Dr. Bello has over 25 years of experience in oncology drug development and has worked with major pharmaceutical companies, enhancing his potential contribution to Xilio's strategic goals. His appointment is seen as a significant development as the company aims to advance its tumor-activated immuno-oncology therapies and improve patient outcomes while minimizing side effects.
Read more →XLOXilio Therapeutics Announces Closing of $50.0 Million Public Offering
Xilio Therapeutics has successfully closed a public offering that generated gross proceeds of approximately $50 million. This offering involved pre-funded warrants and additional common stock warrants, with the potential for total proceeds to reach $150 million if certain warrants are exercised by the end of 2026. The financing was co-led by Coastlands Capital and Frazier Life Sciences, alongside significant participation from existing investors. Xilio intends to utilize the proceeds to further develop its cancer therapies and bolster general corporate purposes.
Read more →XLO▼ -34.6%on this newsshared move
Xilio Therapeutics Announces Pricing of $50.0 Million Public Offering
Xilio Therapeutics has announced the pricing of a public offering amounting to $50 million, comprising pre-funded warrants and various series of warrants. This offering is expected to close on June 5, 2025, and aims to enhance the development of the company's immuno-oncology therapies. The potential proceeds from the exercise of the Series B and C warrants could increase total funding to approximately $100 million. The funds will be utilized for both product development and general corporate purposes.
Read more →XLO▼ -34.6%on this newsshared move
Xilio Therapeutics Announces Proposed Public Offering
Xilio Therapeutics, Inc. has announced a proposed underwritten public offering of pre-funded warrants and various series of warrants for purchasing common stock. The proceeds from the offering are intended to support the development of product candidates and assist with general corporate needs. The effectiveness of this offering is contingent upon market conditions, and there are no guarantees regarding its completion or specific terms. Leerink Partners is acting as the sole bookrunner for the offering.
Read more →XLO▼ -34.6%on this newsshared move
Unleashing the Potential of Immuno-Oncology Therapies
Xilio Therapeutics is advancing its pipeline of tumor-activated immunotherapies, leveraging their clinically validated platform technology. Their approach exploits dysregulated MMP activity common across various solid tumors. The company has secured significant funding through partnerships with major players like AbbVie and Gilead. However, they face uncertainties related to ongoing research and the need for additional financial resources to sustain operations beyond early 2026.
Read more →XLO▼ -34.6%on this newsshared move
Xilio Therapeutics Announces Updated Phase 2 Data for Vilastobart, a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer
Xilio Therapeutics has announced updated Phase 2 data for vilastobart, a tumor-activated anti-CTLA-4 monoclonal antibody, in combination with atezolizumab for patients with metastatic microsatellite stable colorectal cancer (MSS CRC). The preliminary objective response rate is 26%, with significant reductions in tumor biomarkers and clinical symptoms. The combination therapy shows a favorable safety profile, with low rates of colitis and immune-related adverse events. This promising data will be presented at the 2025 ASCO Annual Meeting, highlighting vilastobart's potential as a treatment option for MSS CRC patients.
Read more →XLO▲ +8%on this news· ran to +73% by day 3
Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2025 Financial Results Updated Phase 2 data to be presented at ASCO for vilastobart, a tumor-activated, Fc-enhanced, anti-CTLA-4, in combinatio
Xilio Therapeutics has announced significant updates regarding its pipeline and first quarter 2025 financial results. The company reported positive preliminary Phase 2 data for its anti-CTLA-4 candidate vilastobart, showing a 27% objective response rate in patients with metastatic microsatellite stable colorectal cancer. Additionally, Xilio is advancing multiple masked T cell engager programs, with development candidates expected to launch in the second half of 2025. The company anticipates that its financial resources will sustain operations through the first quarter of 2026.
Read more →XLOXilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Xilio Therapeutics has announced the grant of a non-qualified stock option to purchase 5,000 shares of common stock to a new employee, effective May 1, 2025. This grant is part of the company's 2022 Inducement Stock Incentive Plan and adheres to Nasdaq Listing Rule 5635(c)(4). The exercise price for the stock options is set at $0.755 per share, matching the closing stock price on that date, and the options will vest over a ten-year period. This move signifies the company’s strategy to attract talent in the biotechnology sector.
Read more →XLOXilio Therapeutics to Present Updated Phase 2 Data for Vilastobart, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, in Combination with Atezolizumab in Patients with Microsatellite Stable Colorectal Cancer at the 2025 ASCO Annual Meeting
Xilio Therapeutics plans to present updated data from its Phase 2 trial of vilastobart, an investigational anti-CTLA-4 monoclonal antibody, combined with atezolizumab for treating metastatic microsatellite stable colorectal cancer. The presentation is scheduled for the 2025 ASCO Annual Meeting in Chicago. This development follows a collaboration with Roche to evaluate the effectiveness of this combination therapy. As the trial is ongoing, the final results and their implications remain to be seen.
Read more →XLO▼ -6.2%on this news
Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2024 Financial Results Additional Phase 2 data for vilastobart, a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with
Xilio Therapeutics announced significant progress in its pipeline and business updates, featuring promising Phase 2 data for vilastobart, a tumor-activated anti-CTLA-4. The data indicated a 27% objective response rate in patients without liver metastases, alongside a low incidence of immune-related adverse events. The company is also advancing several masked T cell engager programs and has partnered with AbbVie to explore new tumor-activated immunotherapies. Financially, Xilio expects to sustain operations into early 2026 with current funds and future collaboration payments.
Read more →XLOXilio Therapeutics to Present at TD Cowen 45th Annual Health Care Conference
Xilio Therapeutics, a biotechnology firm specializing in tumor-activated immuno-oncology therapies, announced that CEO Ren Russo will speak at the TD Cowen 45th Annual Health Care Conference. The presentation is scheduled for March 3, 2025, at 9:50 am EST. A live webcast will be available for viewing on the company's website, and an archived version will be accessible for a month after the event.
Read more →XLO▲ +125.3%on this news
Xilio Therapeutics Announces Multiple Masked T Cell Engager Programs
Xilio Therapeutics has announced the initiation of multiple preclinical programs for masked T cell engagers designed to target specific cancer antigens. In conjunction with this, the company entered a collaboration with AbbVie, which provides Xilio with $52 million upfront and potential future contingent payments of up to $2.1 billion. These agreements extend Xilio’s cash runway into the first quarter of 2026, supporting their research and development efforts. The success of these programs is dependent on securing additional capital and overcoming inherent clinical risks associated with T cell engagers.
Read more →XLO▲ +125.3%on this news
AbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies Collaboration will combine AbbVie's oncology expertise and Xilio's proprietary tumor-activation t
AbbVie and Xilio Therapeutics have announced a collaboration to develop novel tumor-activated immunotherapies, leveraging Xilio's advanced technology. The agreement includes a $52 million upfront payment, with the potential for up to $2.1 billion in contingent payments. This partnership aims to generate next-generation cancer treatments by focusing on tumor-selective activation, potentially improving patient outcomes. Both companies believe this collaboration will enhance their efforts in oncology research and development.
Read more →XLO▲ +11.4%on this news· ran to -28% by day 3
Xilio Therapeutics Announces Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer
Xilio Therapeutics announced initial Phase 2 data for vilastobart (XTX101), a tumor-activated anti-CTLA-4, in combination with atezolizumab for treating metastatic microsatellite stable colorectal cancer (MSS CRC). The trial showed a preliminary response rate of 27%, with significant reductions in tumor biomarkers and improvement in clinical symptoms. The data also indicated a favorable safety profile with a low incidence of adverse events. Xilio plans to present further data and additional follow-ups later in the year.
Read more →XLOThis presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding plans, timing and expectat
Xilio's recent presentation revealed promising results for its tumor-activated therapy, XTX501, demonstrating enhanced survival and favorable tolerability in preclinical models. The data indicates that XTX501 achieves antibody-like pharmacokinetics while minimizing peripheral effects, suggesting its potential for better patient outcomes. Preclinical efficacy studies show substantial tumor cell killing and improved immune response compared to existing therapies. This positions XTX501 as a novel immuno-oncology candidate aimed at transforming treatment paradigms for cancer.
Read more →XLO▲ +8.3%on this news· ran to +48% by day 1
Xilio Therapeutics to Present Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer at ASCO GI
Xilio Therapeutics has announced plans to present initial Phase 2 data for vilastobart (XTX101), an anti-CTLA-4 therapy, in combination with atezolizumab for metastatic colorectal cancer at the upcoming ASCO GI symposium. The company also reported positive preliminary data from its Phase 1 trial of XTX301, an investigational tumor-activated IL-12, highlighting its promising clinical profile without dose-limiting toxicities. Furthermore, Xilio completed a private placement with Gilead Sciences, securing substantial funding to support its ongoing development efforts.
Read more →XLOXilio Therapeutics Appoints Caroline Hensley as Chief Legal Officer
Xilio Therapeutics has appointed Caroline Hensley as its new Chief Legal Officer. Hensley brings extensive experience in biotechnology law and compliance, having previously served at Seres Therapeutics and Latham & Watkins. CEO Renée Russo expressed confidence in Hensley's strategic insights and legal expertise, anticipating her contribution to the company's growth. Hensley looks forward to advancing Xilio's immuno-oncology therapies at this pivotal moment for the company.
Read more →XLO▼ -19.4%on this news
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2024 Financial Results Will present initial Phase 1C dose escalation data for vilastobart (XTX101), a tumor-activated, Fc-enhanced anti-CTLA-4,
Xilio Therapeutics has announced significant updates on its pipeline and third quarter financial results. The company is set to present initial Phase 1C dose escalation data for vilastobart (XTX101) combined with atezolizumab at the SITC Annual Meeting. Additionally, Xilio anticipates reporting further clinical data for vilastobart in microsatellite stable colorectal cancer and for XTX301 in late 2024. Strong financial projections indicate that current resources will support operations through mid-2025, enabling ongoing development of their immuno-oncology therapies.
Read more →XLO▼ -19.4%on this news
Xilio Therapeutics Announces Initial Clinical Trial Data from Phase 1C Dose Escalation for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Advanced Solid Tumors
Xilio Therapeutics announced initial results from its Phase 1C trial evaluating the combination of vilastobart and atezolizumab in patients with advanced solid tumors. The trial showed early evidence of anti-tumor activity, including partial responses in two patients with difficult-to-treat tumors, and one patient experienced complete resolution of a liver lesion. The safety profile was favorable, with the combination well-tolerated among participants. Xilio plans to share further Phase 2 trial data by late 2024.
Read more →XLO▲ +38.4%on this news
Xilio Therapeutics to Present Initial Phase 1C Dose Escalation Data for XTX101 (Vilastobart) in Combination with Atezolizumab in a Late-Breaker Poster at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
Xilio Therapeutics has announced that initial data from its Phase 1C dose escalation study of XTX101 (vilastobart) in combination with atezolizumab will be presented at the Society for Immunotherapy of Cancer's 39th Annual Meeting in November 2024. This investigational therapy targets advanced solid tumors and is part of a co-funded trial with Roche. The poster presentation is set to highlight the combination's potential efficacy and safety. Xilio aims to demonstrate innovative approaches in tumor-activated immunotherapy.
Read more →XLO▲ +7.5%on this news
Xilio Therapeutics Announces Upcoming Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
Xilio Therapeutics, Inc. has announced it will present a poster at the Society for Immunotherapy of Cancer's 39th Annual Meeting in Houston, Texas, scheduled for November 6-10, 2024. The presentation will focus on preclinical data related to its innovative tumor-activated immune cell engagers, specifically highlighting their protease-dependent activation and anti-tumor efficacy. This opportunity at a prominent industry meeting may bolster the company's standing in the immuno-oncology field.
Read more →XLO▼ -11%on this news
Xilio Therapeutics to Present at Morgan Stanley 22nd Annual Global Healthcare Conference
Xilio Therapeutics, a biotechnology company focused on immuno-oncology therapies, has announced its participation in the upcoming Morgan Stanley 22nd Annual Global Healthcare Conference. Renée Russo, the CEO of Xilio, will engage in a fireside chat scheduled for September 4, 2024, at 7:00 am EDT. This presentation will provide insights into the company's developments and research on cancer treatments. The event underscores Xilio's ongoing commitment to advancing cancer therapy options.
Read more →XLOXilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2024 Financial Results Initiated enrollment in Phase 2 clinical trial of XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4, in combination wi
Xilio Therapeutics has announced significant advancements in its clinical pipeline, including the initiation of Phase 2 enrollment for XTX101, a tumor-activated anti-CTLA-4 antibody, in combination with atezolizumab for microsatellite stable colorectal cancer. Additionally, the company has begun a Phase 1B monotherapy dose expansion for XTX301, an engineered IL-12 aimed at enhancing anti-tumor immunity. With a solid cash position of $74.9 million, Xilio expects to fund operations through mid-2025. They are set to report clinical data for XTX101 and XTX301 later in 2024.
Read more →XLOXilio Therapeutics Appoints Aoife Brennan, M.D., and James Shannon, M.D., to its Board of Directors
Xilio Therapeutics has announced the appointment of Dr. Aoife Brennan and Dr. James Shannon to its board of directors. Dr. Brennan brings over 16 years of leadership in drug development, while Dr. Shannon contributes more than 30 years of experience in the biotechnology field. Their expertise is expected to enhance Xilio's efforts in advancing its pipeline of tumor-activated immuno-oncology therapies, which aim to address systemic toxicities associated with current treatments. The company anticipates achieving significant clinical milestones in the upcoming year.
Read more →XLOXilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2024 Financial Results Expect to initiate Phase 2 trial for XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizuma
Xilio Therapeutics has announced significant updates regarding its clinical pipeline and financial results for Q1 2024. The company expects to initiate a Phase 2 trial for XTX101 in combination with atezolizumab for patients with microsatellite stable colorectal cancer in Q3 2024. Additionally, clinical data for both XTX101 and XTX301 is set to be reported in Q4 2024, showing potential advancements in their immuno-oncology therapies. Xilio also anticipates having sufficient funding to support operations through the second quarter of 2025.
Read more →XLO▲ +41.7%on this news
Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial Results On track with plans to initiate Phase 2 trial for XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4, in
Xilio Therapeutics has announced significant progress in its pipeline, including plans to initiate a Phase 2 clinical trial for XTX101, a tumor-activated anti-CTLA-4 therapy, in patients with microsatellite stable colorectal cancer in Q3 2024. The company has granted Gilead exclusive rights to develop XTX301, a tumor-activated IL-12, and has reported robust financial results indicating operational funding into mid-2025. Xilio remains focused on advancing its immuno-oncology therapies, including XTX101, XTX301, and XTX202, while expecting key clinical data later this year.
Read more →XLO▲ +69%on this newsshared move
Xilio Info Investors: Melissa Forst Argot Partners Xilio@argotpartners.com Media: Dan Budwick 1AB dan@1abmedia.com Gilead Info Investors: Jacquie Ross investor_relations@gilead.com Media: Meaghan Smith public_af
Gilead Sciences, Inc. and Xilio Therapeutics, Inc. have announced an exclusive licensing agreement for Xilio's tumor-activated IL-12 program, XTX301, which is currently in Phase 1 clinical trials. Under the terms, Gilead will pay $43.5 million upfront and potential additional payments totaling $604 million, highlighting both companies' commitment to advancing cancer therapies. The partnership is expected to leverage Gilead's expertise and resources to further develop treatments for challenging solid tumors. XTX301 is designed to optimize anti-tumor activity within the tumor microenvironment, with hopes of overcoming traditional therapy limitations.
Read more →XLO▲ +69%on this newsshared move
Xilio Therapeutics Announces $11.3 Million Private Placement Equity Financing
Xilio Therapeutics has announced an $11.3 million private placement to advance its tumor-activated immuno-oncology programs, particularly XTX301 and XTX101. Alongside this financing, the company has entered an exclusive license agreement with Gilead for XTX301, receiving $43.5 million upfront and potential future payments. Despite these advancements, Xilio is undertaking a workforce reduction of about 21% to streamline operations, while also discontinuing further investment in XTX202 as a monotherapy. The company anticipates sufficient cash reserves to maintain operations through Q2 2025.
Read more →XLO▲ +5.6%on this news· ran to +17% by day 3
Xilio Therapeutics to Participate in Novel Immuno-Oncology Panel at TD Cowen 44th Annual Health Care Conference
Xilio Therapeutics, a biotechnology company focused on immuno-oncology therapies, announced its participation in the TD Cowen 44th Annual Health Care Conference. CEO Renée Russo will join a panel discussion titled 'Novel Immuno-Oncology' on March 4, 2024. Attendees can access a live webcast of the event through the company's website, which will also host a replay for 30 days afterward. This engagement illustrates Xilio's commitment to advancing cancer treatment discussions.
Read more →XLOXilio Therapeutics to Present at Guggenheim 6th Annual Biotechnology Conference
Xilio Therapeutics, a clinical-stage biotechnology company, announced that its CEO, René Russo, will participate in a fireside chat at the Guggenheim 6th Annual Biotechnology Conference on February 7, 2024. The event will focus on tumor-activated immuno-oncology therapies developed by the company for cancer patients. A live webcast of the discussion will be available on their website, along with a replay accessible for 30 days post-event. This participation reflects Xilio's ongoing efforts in innovation and investor transparency.
Read more →XLOXilio Therapeutics Highlights Recent Advances Across Clinical Pipeline and Encouraging Preliminary Phase 1 Safety Data for XTX301, a Tumor-Activated IL-12, Further Validating the Promise of Its Tumor-Activated Immuno-Oncology Therapies
Xilio Therapeutics announced promising advancements in its clinical pipeline, particularly for XTX301, a tumor-activated IL-12, showing no dose-limiting toxicities at doses nearly 100 times the maximum tolerated dose of rhIL-12 in an ongoing Phase 1 trial. The company also initiated dosing for XTX101 in a Phase 1/2 trial alongside atezolizumab. Additionally, plans to report Phase 2 trial data for XTX202 are set for the first quarter of 2024, reflecting rapid enrollment in ongoing studies. The developments highlight potential breakthroughs in Xilio's tumor-activated immuno-oncology therapies targeted at solid tumors.
Read more →XLOXilio Therapeutics Announces Initiation of Enrollment for Phase 1 Combination Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, and Updated Phase 1 Monotherapy Data Phase 1 combination dose escalation expected
Xilio Therapeutics announced the initiation of patient enrollment for a Phase 1 combination trial of XTX101 alongside atezolizumab, aimed at treating microsatellite stable colorectal cancer (MSS CRC). The updated Phase 1 monotherapy data revealed promising safety and efficacy outcomes, with a reported 33% disease control rate in heavily pre-treated patients with advanced solid tumors. The company also highlighted a notable case of a patient with advanced PD-L1 negative non-small cell lung cancer achieving complete resolution of liver metastases. Future plans include advancing to a Phase 2 trial pending successful outcomes from the current studies.
Read more →XLO▼ -13%on this news· ran to -29% by day 3
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2023 Financial Results Demonstrated initial clinical validation of tumor-selective activation technology for both XTX101, a tumor-activated, Fc
Xilio Therapeutics has announced significant updates concerning its clinical pipeline and financial results for Q3 2023. The company reported initial clinical validation of its tumor-selective activation technologies for its drug candidates XTX101 and XTX202, with XTX202 showing a 50% disease control rate at higher doses. Xilio is on track to commence a trial for XTX101 in combination with atezolizumab in Q4 2023 and anticipates preliminary safety data for XTX301. The overall financial health appears stable, with cash expected to support operations through mid-2024.
Read more →XLO▼ -10%on this news· ran to -33% by day 3shared move
Xilio Announces Initial Monotherapy Safety and Anti-Tumor Activity Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, in Late Line Patients with Advanced Solid Tumors Initial evidence of dose-dependent dise
Xilio Therapeutics announced initial results from its Phase 1/2 clinical trial of XTX202, an engineered IL-2 designed for tumor activation in advanced solid tumors. The data indicated a 50% disease control rate at the higher dosing level of 2.8 mg/kg, with primarily mild adverse events. Importantly, the results suggest that XTX202 is well-tolerated over long-term treatment, as demonstrated by two patients remaining on the therapy for over a year. Xilio plans to further evaluate XTX202 at higher doses in an ongoing Phase 2 trial targeting melanoma and renal cell carcinoma, alongside opportunities for combination therapies.
Read more →XLOXilio Announces Initial Monotherapy Safety and Anti-Tumor Activity Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, in Late Line Patients with Advanced Solid Tumors
Xilio Therapeutics announced initial data from its Phase 1/2 trial of XTX202, revealing promising anti-tumor activity and safety profiles in patients with advanced solid tumors. The study showed a 50% disease control rate at higher doses, with treatment-related adverse events mainly being mild (Grade 1-2). Notably, two patients treated for more than one year demonstrated the drug's potential for long-term tolerability. Xilio plans to advance XTX202 in ongoing trials for metastatic melanoma and renal cell carcinoma.
Read more →XLOXilio to Host Virtual Investor Conference Call and Webcast on Monday, November 6, 2023 to Review Progress Across Pipeline, Including Phase 1/2 Clinical Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, Presented at the SITC Annual Meeting
Xilio Therapeutics, Inc. announced it will host a virtual investor conference call and webcast on November 6, 2023, to discuss progress in its pipeline. This will include presenting Phase 1/2 clinical data for XTX202 at the SITC Annual Meeting from November 1-5, 2023. The company aims to highlight advancements in their tumor-activated immuno-oncology therapies. Leadership from Xilio, alongside a key clinical investigator, will provide insights during the call.
Read more →XLOXilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
Xilio Therapeutics, Inc. has announced that it will present at the Society for Immunotherapy of Cancer's 38th Annual Meeting in San Diego. The presentations will include preliminary data on the anti-tumor activity and safety of XTX202 from a Phase 1/2 clinical trial. Additionally, preclinical data for XTX301 will be shared, which is another promising candidate in their pipeline. These presentations are scheduled to take place from November 1-5, 2023.
Read more →XLOXilio Therapeutics Announces Promotion of Katarina Luptakova, M.D., to Chief Medical Officer and Scott Coleman, Ph.D., to Chief Development Officer Martin Huber, M.D., to leave Xilio Therapeutics and remain an advisor
Xilio Therapeutics has announced the promotions of Dr. Katarina Luptakova to Chief Medical Officer and Dr. Scott Coleman to Chief Development Officer, effective September 5, 2023. Dr. Luptakova succeeds Dr. Martin Huber, who will leave the company to pursue a CEO opportunity but will continue as an advisor. The leadership changes are part of a succession planning process, aiming to leverage the company's internal talent as it advances its tumor-activated immuno-oncology therapies. Both promotions coincide with recent encouraging early clinical trial data.
Read more →XLOXilio Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare Conference
Xilio Therapeutics, a clinical-stage biotechnology company focused on immuno-oncology therapies, announced its participation in the Morgan Stanley 21st Annual Global Healthcare Conference. CEO Renée Russo will engage in a fireside chat scheduled for September 11, 2023. The event underscores the company's commitment to showcasing its innovations in cancer treatment and fostering investor relations. A live webcast of the chat will be available on Xilio's website, along with a replay for 30 days post-event.
Read more →XLOXilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2023 Financial Results Xilio entered into clinical trial collaboration with Roche to evaluate XTX101, a tumor-activated, Fc-enhanced anti-CTLA
Xilio Therapeutics has made significant pipeline and business updates along with its second quarter 2023 financial results. The company has entered a collaboration with Roche for the clinical evaluation of XTX101, which has shown promising initial results in its Phase 1 trial. Xilio anticipates reporting preliminary data for XTX202 and XTX301 later this year, while maintaining a strong financial position with sufficient funds for operations into mid-2024.
Read more →XLOXilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2023 Financial Results
Xilio Therapeutics has announced several pipeline and business updates, including a collaboration with Roche to evaluate its investigational anti-CTLA-4 agent, XTX101, in combination with atezolizumab for patients with microsatellite stable colorectal cancer. The company reported promising data from its Phase 1 trial of XTX101, including a partial response in some patients and a favorable safety profile. Xilio also plans to report preliminary data for its other investigational drugs, XTX202 and XTX301, by the end of 2023, while maintaining a strong financial position with significant cash reserves.
Read more →XLOXilio Therapeutics Announces Promotion of Chris Frankenfield to Chief Operating Officer
Xilio Therapeutics has promoted Chris Frankenfield to Chief Operating Officer, highlighting his leadership role in the company's growth. Frankenfield brings over 15 years of biotech experience, having served previously as the Chief Legal and Administrative Officer and General Counsel. The CEO expressed confidence in Frankenfield's ability to continue advancing Xilio's strategic initiatives for its pipeline of immuno-oncology treatments. This move reflects Xilio's commitment to developing innovative therapies for cancer treatment.
Read more →XLOXilio Therapeutics Announces Preliminary Clinical Data from Phase 1 Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, in Patients with Advanced Solid Tumors
Xilio Therapeutics has announced preliminary clinical data from its Phase 1 trial of XTX101, indicating encouraging anti-tumor activity in patients with advanced solid tumors, particularly one case of partial response in a patient with PD-L1 negative non-small cell lung cancer. The safety profile appears favorable, with no significant dose-limiting toxicities reported at the recommended Phase 2 dose of 150 mg every six weeks. The company plans to further explore the potential of XTX101 in combination therapies for historically immunotherapy-resistant tumor types.
Read more →XLOXilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2023 Financial Results Initiated Phase 2 clinical trial for XTX202, a tumor-activated IL-2 Anticipate reporting preliminary Phase 1 safety, PK,
Xilio Therapeutics has announced significant advancements in its clinical pipeline, including the initiation of a Phase 2 trial for XTX202, a tumor-activated IL-2 therapy targeting advanced renal cell carcinoma and melanoma. The company also expects to report preliminary data from its Phase 1 trial of XTX101 later this quarter. Financially, Xilio ended Q1 2023 with $93.3 million in cash, expected to sustain operations through mid-2024. In addition, Xilio has two abstracts accepted for presentation at the 2023 ASCO Annual Meeting, further demonstrating its ongoing commitment to oncology research.
Read more →XLO▼ -7.4%on this news
Xilio Therapeutics Announces Pipeline and Business Updates for the Fourth Quarter and Full Year 2022 Financial Results Initial clinical data from XTX101, XTX202 and XTX301 clinical trials anticipated in 2023 XTX202, a tu
Xilio Therapeutics reported significant progress in its pipeline and business updates for 2022, particularly its tumor-activated immuno-oncology programs: XTX101, XTX202, and XTX301. The company anticipates initial clinical data from these trials in 2023, with a Phase 2 monotherapy trial for XTX202 commencing in April. Notably, preliminary evidence demonstrated XTX202's selective activation within tumors. Xilio ended 2022 with solid financial positioning, expecting to sustain operations into the second quarter of 2024.
Read more →XLO▲ +5.7%on this newsshared move
Xilio Therapeutics to Present at Upcoming Investor Conferences
Xilio Therapeutics, a biotechnology company focused on tumor-activated immuno-oncology therapies, has announced its upcoming participation in two significant investor conferences. The Cowen 43rd Annual Healthcare Conference will take place on March 6, 2023, followed by the Oppenheimer 33rd Annual Healthcare Conference on March 13, 2023. Both events will feature presentations that can be accessed through the company's website, highlighting their commitment to investor engagement and transparency.
Read more →XLOXilio Therapeutics to Present at the Citi 2023 Virtual Oncology Leadership Summit
Xilio Therapeutics, a biotechnology company that focuses on tumor-activated immuno-oncology therapies, has announced its participation in the Citi 2023 Virtual Oncology Leadership Summit. CEO René Russo will present at the event, scheduled for February 23, 2023. The presentation will provide insights into the company's advancements in oncology and can be accessed via live webcast on the company's website.
Read more →XLOXilio Therapeutics to Present at the Guggenheim Healthcare Talks Oncology Day
Xilio Therapeutics, a biotechnology company focused on tumor-activated immuno-oncology therapies, announced that CEO Renée Russo will present at the Guggenheim Healthcare Talks Oncology Day. The event is scheduled for February 9, 2023, and will include a live webcast available for audience access. A replay will be archived for 30 days following the presentation, highlighting the company's commitment to investor engagement.
Read more →XLOUnleashing the Potential of Immuno - Oncology Therapies
Xilio Therapeutics is advancing its immuno-oncology pipeline with compounds XTX101 and XTX301. Enrollment is ongoing for the Phase 1 trial of XTX101, while XTX301 is poised to initiate monotherapy dose-escalation trials. The company is focusing on strategic partnerships to support further development, particularly for Phase 2 trials. Despite promising preclinical data, Xilio faces financial pressures and has reported increased research and development costs.
Read more →XLO▲ +7.9%on this news
Xilio Therapeutics to Host Live Virtual Program Spotlighting XTX301, a Tumor-Activated IL-12
WALTHAM, Mass., Nov. 23, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that the company will host a live virtual program on Thursday, Dec
Read more →XLOXilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2022 Financial Results XTX202, a tumor-activated IL-2, successfully reached target dose range of 1 mg/kg in ongoing Phase 1 clinical trial; pre
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2022 Financial Results XTX202, a tumor-activated IL-2, successfully reached target dose range of 1 mg/kg in ongoing Phase 1 clinical trial; preliminary evidence of increased CD8+ effector T cells and NK
Read more →XLOXilio Therapeutics to Present at Cowen 6th Annual ‘IO Next’ Summit
WALTHAM, Mass., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that the company will participate in a virtual fireside chat at th
Read more →XLOXilio Therapeutics to Present at Guggenheim Nantucket Therapeutics Conference
WALTHAM, Mass., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer, today announced that the company will participate in a fireside chat at the Gugge
Read more →XLO▲ +15.4%on this news
Xilio Therapeutics Appoints Tomas J. Heyman to Board of Directors
WALTHAM, Mass., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer, today announced the appointment of Tomas J. Heyman to the company’s board of dire
Read more →XLO▲ +8.2%on this news· ran to +33% by day 3
Xilio Therapeutics to Present at Morgan Stanley 20th Annual Global Healthcare Conference
WALTHAM, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer, today announced that the company will participate virtually in a fireside chat at
Read more →XLO▼ -26.2%on this news
Xilio Therapeutics Announces Encouraging Preliminary Phase 1 Dose-Escalation Data for XTX101, a Tumor-Selective Anti-CTLA-4, and Reports Pipeline and Business Updates and Second Quarter 2022 Financial Results
Xilio Therapeutics Announces Encouraging Preliminary Phase 1 Dose-Escalation Data for XTX101, a Tumor-Selective Anti-CTLA-4, and Reports Pipeline and Business Updates and Second Quarter 2022 Financial Results XTX101, tumor-selective anti-CTLA-4, has successfully reached dose lev
Read more →XLOXilio Therapeutics Announces Promotion of Martin Huber, M.D., to President
Paul Clancy Elected as Chair of the Board of Directors Robert Ross, M.D., Appointed to Board of Directors WALTHAM, Mass., June 16, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for p
Read more →XLO▼ -9.6%on this news
Xilio Therapeutics to Present at the H.C. Wainwright Global Investment Conference
WALTHAM, Mass., May 18, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer, today announced that Marty Huber, M.D., president of research and development and c
Read more →XLO▼ -5.2%on this news· ran to -22% by day 3shared move
Xilio Therapeutics Appoints Stacey Davis as Chief Business Officer
WALTHAM, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer, today announced that Stacey Davis has been appointed as chief business officer to f
Read more →XLOXilio Therapeutics Reports Pipeline and Business Highlights and First Quarter 2022 Financial Results Clinical programs for XTX202, a tumor-selective IL-2, and XTX101, a tumor-selective anti-CTLA-4, continue to advance wi
Xilio Therapeutics Reports Pipeline and Business Highlights and First Quarter 2022 Financial Results Clinical programs for XTX202, a tumor-selective IL-2, and XTX101, a tumor-selective anti-CTLA-4, continue to advance with preliminary data anticipated in 2022 On track with plan
Read more →XLOXilio Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference
WALTHAM, Mass., April 07, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer, today announced that Marty Huber, M.D., president of research and development and
Read more →XLO▼ -7.6%on this news· ran to -27% by day 3
Xilio Therapeutics Reports Pipeline and Business Progress and Fourth Quarter and Full Year 2021 Financial Results Initial Phase 1 Data Readouts from Clinical Trials of XTX101 and XTX202 Anticipated in 2022 On Track with
Xilio Therapeutics Reports Pipeline and Business Progress and Fourth Quarter and Full Year 2021 Financial Results Initial Phase 1 Data Readouts from Clinical Trials of XTX101 and XTX202 Anticipated in 2022 On Track with Plans to Submit IND for XTX301 in Second Half of 2022 Con
Read more →XLO▼ -10.4%on this news· ran to -31% by day 3shared move
Xilio Therapeutics to Participate in the Cowen 42nd Annual Healthcare Conference
WALTHAM, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer, today announced that René Russo, Pharm.D., president and chief executive officer,
Read more →XLOXilio Therapeutics to Participate in the Guggenheim 4th Annual Oncology Day
WALTHAM, Mass., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer, today announced that René Russo, Pharm. D., president and chief executive officer,
Read more →XLO▲ +9.8%on this news
Xilio Therapeutics Announces Initiation of Patient Dosing in Phase 1/2 Clinical Trial of XTX202 for the Treatment of Patients with Solid Tumors
WALTHAM, Mass., Jan. 20, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer, today announced that the first patient has been dosed in the company’s Phase 1/2 c
Read more →XLOXilio Therapeutics Appoints Yuan Xu, Ph.D., to its Board of Directors
Xilio Therapeutics Appoints Yuan Xu, Ph.D., to its Board of Directors WALTHAM, Mass., January 6, 2022 - Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer, today announced the appoint
Read more →XLOXilio Therapeutics Reports Pipeline and Business Progress and Third Quarter 2021 Financial Results Anticipate First Patient Dosing in Phase 1/2 Clinical Trial for XTX202, a Tumor-Selective IL-2, in First Quarter of 2022
Xilio Therapeutics Reports Pipeline and Business Progress and Third Quarter 2021 Financial Results Anticipate First Patient Dosing in Phase 1/2 Clinical Trial for XTX202, a Tumor-Selective IL-2, in First Quarter of 2022 Advancing Phase 1/2 Clinical Trial for XTX101, a Tumor-Sel
Read more →XLOXilio Therapeutics Announces Preclinical Data Demonstrating Anti-Tumor Activity and Tolerability of XTX301, a Tumor-Selective IL-12, at Society for Immunotherapy in Cancer Annual Meeting
WALTHAM, Mass., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq:XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for patients with cancer, today announced data from preclinical studies of XTX301, an engineered tumor-selective i
Read more →XLOXilio Therapeutics Announces Closing of Initial Public Offering
WALTHAM, Mass., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Xilio) a biotechnology company developing tumor-selective immuno-oncology therapies for patients with cancer, today announced the closing of its previously announced initial public offering of 7,353,000 s
Read more →Competitive Position
How XLO ranks across every disease it competes inCompetitive Position is a premium feature
See how XLO ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial